JLinx will be based at subsidiary Janssen's Beerse campus and will be funded by J&J subsidiary Johnson & Johnson Innovation - JJDC.

Pharmaceutical and healthcare company Hutchison China MediTech, which counts Mitsui as an investor, priced its American depositary shares at $13.50 each.

Softbank has contributed to a $55m series C round for the DNA sequencing technology developer that was led by Fidelity Management and Research.

MIT spinout Ribon Therapeutics, which remains in stealth mode, has been revealed to have secured $10m in funding.

The pharmaceutical firm has agreed to supply $50m in cash and services to small-molecule drug developer Dice Molecules as part of a collaboration agreement.

Arterys, the developer of a medical imaging platform for blood flow, has completed a $12m round that included Stanford's StartX Fund.

GV led the genome sequencing spinout's series B round, which followed a $5.5m series A in late 2014.